Pathyaപഥ്യം
← New record

IndiPGx-Pop p119

Lab reportcohort · india-sim

10/30/2026, 1:58:35 PM · PharmCAT 3.4.0 · Research record, not medical advice

6
Genes standardised
6
Calls quoted
0
Coverage gaps
0
Identifiers removed
23.5s
Upload to record
  1. Muse Sparkread 6 gene calls17.0s
  2. PharmCATstandardised 6 genes6.5s
  3. Rules0 coverage gaps

CallsMuse Spark each call quoted from the source, then standardised by PharmCAT

Example Pharmacogenomics Centre, Mumbai · FOR SOFTWARE TESTING · 24 Oct 2026 · open original photo

Uploaded lab report photo
GeneAs printedStandardisedPhenotype term
CYP2C19“CYP2C19 Phenotype: Rapid metabolizer *2 Not detected *3 Not detected *17 Detected (heterozygous)”*1/*17Rapid Metabolizer
CYP2D6“CYP2D6 Phenotype: Normal metabolizer *2 Not detected *3 Not detected *4 Not detected *5 Not detected *6 Not detected *10 Not detected *41 Not detected”*1/*1Normal Metabolizer · activity 2.0
DPYD“DPYD Phenotype: Normal metabolizer c.1236G>A (HapB3) Not detected c.85T>C (*9A) Not detected c.1905+1G>A (*2A) Not detected c.1679T>G (*13) Not detected c.2846A>T Not detected”Reference/ReferenceNormal Metabolizer · activity 2.0
NUDT15“NUDT15 Phenotype: Normal metabolizer *3 Not detected”*1/*1Normal Metabolizer
TPMT“TPMT Phenotype: Normal metabolizer *2 Not detected *3A Not detected *3B Not detected *3C Not detected”*1/*1Normal Metabolizer
UGT1A1“UGT1A1 Phenotype: Normal metabolizer *28 Not detected *6 Not detected”*1/*1Normal Metabolizer

Method as printed: Method: targeted genotyping by real-time PCR. Only the listed variants are assayed; variants outside this panel cannot be excluded. DPYD tested: c.1236G>A (HapB3), c.85T>C (*9A), c.1905+1G>A (*2A), c.1679T>G (*13), c.2846A>T. UGT1A1 tested: *28, *6. TPMT tested: *2, *3A, *3B, *3C. NUDT15 tested: *3. CYP2C19 tested: *2, *3, *17. CYP2D6 tested: *2, *3, *4, *5, *6, *10, *41.

Coveragedeterministic rules · which India-relevant variants this panel named

DPYDHapB3named on the report

Most common Indian decreased-function DPYD variant (~3.3%, PMID 40810747)

DPYDc.85T>C (*9A)named on the report

~25% in Indians; toxicity signal in South Indian cohorts (PMC11300675)

DPYD*2Anamed on the report

European tier-1 variant; rare in Indians (PMID 40810747)

DPYD*13named on the report

Tier-1 no-function variant (PMID 39032821)

DPYDc.2846A>Tnamed on the report

Tier-1 variant; near-absent in Indians (PMID 40810747)

NUDT15*3named on the report

Main NUDT15 risk allele, ~7-11% in Indians (PMID 29470173)

UGT1A1*28named on the report

TA-repeat allele, common in South Asians

UGT1A1*6named on the report

East Asian allele; reported at low frequency in India

TPMT*3Cnamed on the report

Most common TPMT variant in South Asians

CYP2C19*2named on the report

Common no-function allele in South Asians

CYP2C19*17named on the report

Increased-function allele

A variant the panel did not name is left out of cohort statistics for that variant, rather than counted as absent. Reader notes: Only the listed variants are assayed; variants outside this panel cannot be excluded. Synthetic document generated for software benchmarking. Not a real patient or laboratory.

Exportde-identified · the same record in three formats

Curator review

A curator checks each call against the source document before the record counts in a cohort, and Muse Spark web search finds published Indian frequency data for each variant. Both are written to the audit log. Reviewing is the one action that needs a curator code, because it is a claim that a person checked the page.

Sign in as a curator
Research tool, not medical advice. Pathya reads and standardises pharmacogenomic results; it makes no dose, drug or test recommendation. Audit log: data/cases/71f81caa4b10/audit.log.